Arcus Biosciences

$27.20 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Arcus Biosciences

Arcus Biosciences, Inc. is a clinical-stage biotechnology company focused on developing cancer immunotherapy. The Company has developed drug discovery capability designed to create differentiated small molecules, which has the ability to develop in combinations with its monoclonal antibodies through rationally designed, indication-specific, adaptive clinical trial designs. The Company is focused on creating, developing and commercializing differentiated combination cancer therapies that have the potential to cure. The Company has four clinical-stage investigational products: AB928, AB154, Zimberelimab and AB680.

Stock Analysis

last close $25.88
1-mo return -5.5%
3-mo return 50.2%
avg daily vol. 651.72T
52-week high 49.1
52-week low 16.74
market cap. $2.0B
forward pe -
annual div. -
roe 9.9%
ltg forecast -
dividend yield -
annual rev. $409M
inst own. 68.6%

Subscribe now for daily local and international financial news